Thus, targeting PD-L1 as a CAR T cell antigenis an exciting strategy.By targeting cancer cells overexpressing PD-L1, CAR T cells can notonly be guided to attack cancer cells but also neutralize the immunosuppressivePD-1/PD-L1 axis and mitigate T cell exhaustion. The gene discussed is CD274; the disease is cancer.